Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

a study in type 1 diabetes patients who receive their insulin treatment via pump. The study demonstrated that pre-administration of rHuPH20 led to consistent insulin exposure over the infusion set life and better glucose control following meals.
  • Reported results from two Phase 2 clinical trials of its ultrafast rHuPH20 insulin analog formulations in patients with Type 1 and Type 2 diabetes. Both trials met the primary endpoint of non-inferiority of HbA1C compared to insulin analog. rHuPH20 insulin analog use resulted in a greater than 50% increase in the proportion of patients able to consistently (i.e. during at least 2/3 of meals) achieve AACE (American Association of Clinical Endocrinologists) guidelines for post-prandial glucose targets at both one and two hours after meals in both Type 1 and Type 2 patients.
  • Initiated a Phase 2 study with PEGPH20 in patients with stage IV previously untreated pancreatic cancer.
  • Initiated a Phase 1/2 study with HTI-501 in women with moderate to severe edematous fibrosclerotic panniculopathy, or cellulite.
  • Baxter presented its Phase III data for the HyQ program at the American College of Allergy, Asthma & Immunology.  HyQ was shown to be effective in subjects with Primary Immunodeficiency and enabled 94% of subjects to receive full 3 or 4-weekly doses of IgG using a single site with very good local and systemic tolerability.  Systemic infusion reactions occurred in 8.3% of HyQ infusions compared to 25% of infusions in the IV arm. HyQ also demonstrated improved bioavailability compared to IGSC and similar trough levels to IGIV when administered at 3 or 4-week intervals, at infusion rates and times faster than IGIV.  Baxter submitted regulatory applications in the US in the second quarter and in the EU in the third quarter.
  • Achieved a $3 million milestone under ViroPharma agreement triggered by ViroPharma's initiation of an open-label, multi-dose Phase 2 study of Cinryze
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
    2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
    3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
    4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
    5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
    6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
    7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/1/2015)... Md. and RESEARCH TRIANGLE PARK, N.C. ... UTHR ) announced today that Roger Jeffs , ... provide an overview and update on the company,s business at ... in Boston, Massachusetts . The ... 3:30 PM Eastern Time, and can be accessed via a ...
    (Date:4/30/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... it has commenced an underwritten public offering of its ... underwriters a 30-day option to purchase up to an ... offered in the public offering. The offering is subject ... as to whether or when the offering may be ...
    (Date:4/30/2015)... SEATTLE , April 30, 2015  The Paul ... Allen Distinguished Investigator (ADI) grants to six groups of ... the most challenging roadblocks in neuroscience: growing mature human ... at a total of $7.5 million over three years.  ... Investigators and their research is especially significant because the ...
    (Date:4/30/2015)... SAINT-MALO, FRANCE (PRWEB) April 30, 2015 ... States, and at http://www.lespausa.com , ... a multi-action product combining the benefits of makeup, ... formula. This subtly tinted cream is designed with ... blemishes for an even complexion and a healthy ...
    Breaking Biology Technology:BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3
    ... Jolanta Kolodziejek, MSc, and Professor Norbert Nowotny, PhD, Clinical , ... Medicine, , Vienna , Veterinaerplatz 1, A ... Introduction , ... is the most critical factor in nucleotide sequencing. ...
    ... , , L. A. Knapp, 1, 2 E. Lehmann, 2 ... and D. I. Watkins 2, 3 , ... 2 Wisconsin Regional Primate Research Center, University of Wisconsin, , ... University of , Wisconsin Hospital and Clinics, Madison, Wisconsin, U.S.A. ...
    ... Menu B. Leddy, Biotechnology Research Department,Orange County ... , Introduction ... of bacterial species from membrane , ... of bacterial cells from membrane biofilms cannot be ...
    Cached Biology Technology:Comparison of PCR Kleen Spin Columns to Traditional Methods for Purification of PCR Products Prior to Sequencing, Rev A 2Comparison of PCR Kleen Spin Columns to Traditional Methods for Purification of PCR Products Prior to Sequencing, Rev A 3Comparison of PCR Kleen Spin Columns to Traditional Methods for Purification of PCR Products Prior to Sequencing, Rev A 4Separation of HLA-DRB Alleles by Denaturing Gradient Gel Electrophoresis using the DCode System 2Separation of HLA-DRB Alleles by Denaturing Gradient Gel Electrophoresis using the DCode System 3Separation of HLA-DRB Alleles by Denaturing Gradient Gel Electrophoresis using the DCode System 4Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 2Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 3Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 4Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 5Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 6Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 7
    (Date:4/1/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces the second shipment of ... to early access pre-order customers. Feedback ... outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop & ... at all outlets and very easy to use. Several ...
    (Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
    (Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
    Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
    ... In the last decade, a new strain of MRSA has ... risk of contracting the dangerous bacterial infection. This particular strain ... of genes not shared by any other strains, though it ... to survive and persist in the community. Now, research ...
    ... The rate of chemical processes in cells is dictated by ... given reaction. Using a versatile method developed at the Institute ... Warsaw, researchers were able to predict for the first time ... . The achievement is important not only for biologists and ...
    ... the original Otom inhabitants of Xaltocan, the capital of ... long wondered whether they assimilated with the Aztecs or ... research from The University of Texas at Austin, Wichita ... lie in DNA. Following this line of evidence, the ...
    Cached Biology News:UNC study may lead to treatments that are effective against all MRSA strains 2Biologistics: How fast do chemical trains move in living cells? 2Biologistics: How fast do chemical trains move in living cells? 3Aztec conquest altered genetics among early Mexico inhabitants, new DNA study shows 2